TSC2 and cancer: To reduce the effect of activating/silencing gene mutations on mTOR transcriptomic analysis, cell lines with cancer driving genomic alterations in PTEN, mTOR, AKT1, AKT2, AKT3, PI3KCA, TSC1, or TSC2 were excluded.